Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 143580
Corporate User License Price USD 6000
Corporate User License Price INR 430740
Site License Price USD 4000
Site License Price INR 287160
Request a Quote

Report Title

Atrial Fibrillation-Pipeline Review, H2 2016

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Atrial Fibrillation-Pipeline Review, H2 2016


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Atrial Fibrillation-Pipeline Review, H2 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Atrial Fibrillation-Pipeline Review, H2 2016



Executive Summary

Atrial Fibrillation-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Atrial Fibrillation-Pipeline Review, H2 2016', provides an overview of the Atrial Fibrillation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation

The report reviews pipeline therapeutics for Atrial Fibrillation by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Atrial Fibrillation therapeutics and enlists all their major and minor projects

The report assesses Atrial Fibrillation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Atrial Fibrillation

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Atrial Fibrillation Overview 9

Therapeutics Development 10

Pipeline Products for Atrial Fibrillation-Overview 10

Pipeline Products for Atrial Fibrillation-Comparative Analysis 11

Atrial Fibrillation-Therapeutics under Development by Companies 12

Atrial Fibrillation-Therapeutics under Investigation by Universities/Institutes 13

Atrial Fibrillation-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Atrial Fibrillation-Products under Development by Companies 17

Atrial Fibrillation-Products under Investigation by Universities/Institutes 19

Atrial Fibrillation-Companies Involved in Therapeutics Development 20

ARCA biopharma, Inc. 20

AstraZeneca Plc 21

Bristol-Myers Squibb Company 22

Cardiome Pharma Corp. 23

Daiichi Sankyo Company, Limited 24

Dong-A Socio Holdings Co. Ltd. 25

Gilead Sciences, Inc. 26

Laboratoires Pierre Fabre SA 27

Nissan Chemical Industries, Ltd. 28

OMEICOS Therapeutics GmbH 29

Otsuka Holdings Co., Ltd. 30

Xention Limited 31

Atrial Fibrillation-Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

AFC-1-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

BMS-919373-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

bucindolol hydrochloride-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

edoxaban tosylate-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

F-373280-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

flecainide acetate-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Gene Therapy for Atrial Fibrillation-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

GS-967-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

NIP-151-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

OMT-28-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

OPC-108459-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Small Molecule to Block Kv1.5 for Atrial Fibrillation-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Small Molecules to Block GIRK for Atrial Fibrillation-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

STP-023725-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

vernakalant hydrochloride-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

XEN-R0702-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

XEND-0103-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

XENR-0703-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

XENR-0706-Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Atrial Fibrillation-Dormant Projects 78

Atrial Fibrillation-Discontinued Products 83

Atrial Fibrillation-Product Development Milestones 84

Featured News & Press Releases 84

May 11, 2016: Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study 84

May 02, 2016: New drug more effective in treating atrial fibrillation 84

Mar 31, 2016: Cardiome Announces Publication of Independent Study Comparing BRINAVESS to IBUTILIDE in Patients with Recent-Onset Atrial Fibrillation 85

Mar 24, 2016: Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA(edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session 85

Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA 87

Jan 13, 2016: Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia 87

Dec 22, 2015: Cardiome Files New Drug Submission Seeking Canadian Approval Of Intravenous Vernakalant 87

Nov 02, 2015: Daiichi Sankyo, Inc. Announces New Subgroup Analyses of Once-Daily SAVAYSA in Patients with Non-Valvular Atrial Fibrillation Will Be Presented at AHA Scientific Sessions 2015 88

Nov 02, 2015: OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation 89

Sep 23, 2015: UK's NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation 89

Aug 10, 2015: United Kingdom Department of Health Sets BRINAVESS Pricing 91

Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China 91

Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice" 91

Jun 25, 2015: Daiichi Sankyo's Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE 93

Jun 12, 2015: Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation 94

Appendix 96

Methodology 96

Coverage 96

Secondary Research 96

Primary Research 96

Expert Panel Validation 96

Contact Us 96

Disclaimer 97

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for Atrial Fibrillation, H2 2016 10

Number of Products under Development for Atrial Fibrillation-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 (Contd..1) 18

Products under Investigation by Universities/Institutes, H2 2016 19

Atrial Fibrillation-Pipeline by ARCA biopharma, Inc., H2 2016 20

Atrial Fibrillation-Pipeline by AstraZeneca Plc, H2 2016 21

Atrial Fibrillation-Pipeline by Bristol-Myers Squibb Company, H2 2016 22

Atrial Fibrillation-Pipeline by Cardiome Pharma Corp., H2 2016 23

Atrial Fibrillation-Pipeline by Daiichi Sankyo Company, Limited, H2 2016 24

Atrial Fibrillation-Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 25

Atrial Fibrillation-Pipeline by Gilead Sciences, Inc., H2 2016 26

Atrial Fibrillation-Pipeline by Laboratoires Pierre Fabre SA, H2 2016 27

Atrial Fibrillation-Pipeline by Nissan Chemical Industries, Ltd., H2 2016 28

Atrial Fibrillation-Pipeline by OMEICOS Therapeutics GmbH, H2 2016 29

Atrial Fibrillation-Pipeline by Otsuka Holdings Co., Ltd., H2 2016 30

Atrial Fibrillation-Pipeline by Xention Limited, H2 2016 31

Assessment by Monotherapy Products, H2 2016 32

Number of Products by Stage and Target, H2 2016 34

Number of Products by Stage and Mechanism of Action, H2 2016 36

Number of Products by Stage and Route of Administration, H2 2016 38

Number of Products by Stage and Molecule Type, H2 2016 40

Atrial Fibrillation-Dormant Projects, H2 2016 78

Atrial Fibrillation-Dormant Projects (Contd..1), H2 2016 79

Atrial Fibrillation-Dormant Projects (Contd..2), H2 2016 80

Atrial Fibrillation-Dormant Projects (Contd..3), H2 2016 81

Atrial Fibrillation-Dormant Projects (Contd..4), H2 2016 82

Atrial Fibrillation-Discontinued Products, H2 2016 83

List of Figures

Number of Products under Development for Atrial Fibrillation, H2 2016 10

Number of Products under Development for Atrial Fibrillation-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 32

Number of Products by Top 10 Targets, H2 2016 33

Number of Products by Stage and Top 10 Targets, H2 2016 33

Number of Products by Top 10 Mechanism of Actions, H2 2016 35

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 35

Number of Products by Routes of Administration, H2 2016 37

Number of Products by Stage and Routes of Administration, H2 2016 37

Number of Products by Molecule Types, H2 2016 39

Number of Products by Stage and Molecule Types, H2 2016 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

ARCA biopharma, Inc.

AstraZeneca Plc

Bristol-Myers Squibb Company

Cardiome Pharma Corp.

Daiichi Sankyo Company, Limited

Dong-A Socio Holdings Co. Ltd.

Gilead Sciences, Inc.

Laboratoires Pierre Fabre SA

Nissan Chemical Industries, Ltd.

OMEICOS Therapeutics GmbH

Otsuka Holdings Co., Ltd.

Xention Limited

Atrial Fibrillation Therapeutic Products under Development, Key Players in Atrial Fibrillation Therapeutics, Atrial Fibrillation Pipeline Overview, Atrial Fibrillation Pipeline, Atrial Fibrillation Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand